Form 4: Liquidia Corp Chief Commercial Officer Reports Routine Stock Transactions for Tax Purposes

Liquidia Corp's Chief Commercial Officer, Scott Moomaw, reported the acquisition of 15,539 shares of common stock from vested performance stock units and the subsequent sale of 6,656 shares at $16.97 to cover tax obligations.

Summary

• Scott Moomaw, Chief Commercial Officer of Liquidia Corp (LQDA), reported changes in his beneficial ownership of company securities.
• On June 3, 2025, Moomaw acquired 15,539 shares of common stock through the conversion of performance stock units (PSUs).
• These PSUs were part of a grant on January 11, 2024, with vesting contingent on a time-based schedule and the first commercial sale of YUTREPIA by Liquidia Corp.
• Following this acquisition, Moomaw's direct beneficial ownership was 231,577 shares.
• On June 4, 2025, Moomaw sold 6,656 shares of common stock at a price of $16.97 per share.
• This sale was explicitly conducted to cover tax liabilities associated with the settlement of the vested PSUs.
• The sale was executed under a pre-arranged Rule 10b5-1 plan, which was adopted by Moomaw on December 15, 2023.
• After the sale, Moomaw's direct beneficial ownership stands at 224,921 shares.
• His total holdings also include 36,458 unvested restricted stock units (RSUs) from a January 2023 grant, 34,184 unvested RSUs from a January 2024 grant, 69,729 unvested RSUs from a January 2025 grant, and 11,002 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions, including the vesting of equity awards and a subsequent tax-related sale. While a sale reduces insider ownership, it was pre-planned and for a common reason, not indicating negative sentiment towards the company. The vesting of PSUs suggests progress towards company milestones (YUTREPIA commercial sale).

Positives

• The acquisition of shares through PSU vesting indicates the achievement of performance or time-based milestones, including progress towards the commercial sale of YUTREPIA.
• The sale of shares was explicitly for tax purposes, which is a common and often pre-planned event for executive compensation and not typically indicative of a lack of confidence in the company.
• The transaction was conducted under a Rule 10b5-1 plan, demonstrating a pre-arranged and non-discretionary trading strategy, which enhances transparency and reduces concerns about insider trading.

Negatives

• A sale of shares by an insider, even for tax purposes, results in a reduction of their direct equity stake in the company.

Risks

• The vesting of a portion of the PSUs is contingent upon the 'first commercial sale of YUTREPIA by the Issuer,' indicating a dependency on the successful launch and commercialization of this product.

Future Outlook

The vesting schedule for some performance stock units is explicitly tied to the first commercial sale of YUTREPIA, indicating a future key milestone for the company's product launch and commercialization efforts.

Industry Context

This filing represents a routine insider transaction report for a biotechnology or pharmaceutical company. The mention of 'YUTREPIA' suggests a focus on drug development and commercialization, which is a core activity in the biopharma sector. Insider sales for tax purposes are a standard and expected occurrence in executive compensation across various industries.

Comparison to Industry Standards

• Insider transactions, particularly those related to the vesting of equity awards and subsequent tax-related sales, are common across publicly traded companies, especially in industries with significant equity-based compensation like biotechnology.
• The use of a Rule 10b5-1 plan for the sale aligns with best practices for insiders to manage their stock transactions in a pre-planned manner, thereby avoiding accusations of trading on material non-public information. This practice is widely adopted by executives in comparable companies to ensure compliance and transparency.
• The structure of equity compensation, involving Performance Stock Units (PSUs) and Restricted Stock Units (RSUs), is a standard incentive mechanism used by many companies, including peers in the pharmaceutical and biotech sectors, to align executive interests with shareholder value creation and specific operational milestones like product launches.

Stakeholder Impact

• Shareholders: Provides transparency on insider stock movements. The tax-related sale is a routine event and generally not a signal of negative sentiment. The vesting of PSUs could be seen as a positive sign of progress towards company goals (YUTREPIA launch).
• Employees: The report details equity compensation (PSUs, RSUs, ESPP), which is a key component of employee incentives and retention, particularly for executives.

Next Steps

• Monitoring for the first commercial sale of YUTREPIA, as it is a vesting condition for some Performance Stock Units (PSUs).
• Future vesting of remaining unvested Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) as per their respective schedules.

Key Dates

Recommendation

Keywords

Liquidia Corp, LQDA, Form 4, Insider Trading, Stock Ownership, Performance Stock Units, Restricted Stock Units, Rule 10b5-1 Plan, Executive Compensation, YUTREPIA, Biotechnology, Pharmaceuticals